EC Number |
Application |
Reference |
---|
3.4.24.B12 | medicine |
potential target for treatment of osteoarthritis |
652268 |
3.4.24.B12 | medicine |
the first thrombospondin type 1 repeat domain of ADAMTS5, unlike the second, has anti-angiogenic activities, ADAMTS5 is therefore an anti-angiogenic peptide and may serve as a prototype for future development into anti-cancer drugs |
677997 |
3.4.24.B12 | medicine |
therapeutic target in osteoarthritis |
679302 |
3.4.24.B12 | medicine |
stop progression of cartilage degradation in osteoarthritis by prevention of aggrecan cleavage via inhibition of aggrecanase |
696674 |
3.4.24.B12 | more |
neurite extension mediated by the MAP kinase pathway, increased number of primary and secondary neurites |
697804 |
3.4.24.B12 | medicine |
a single injection of ADAMTS5 siRNA induces the suppression of degradation in nucleus pulposus tissues |
707311 |
3.4.24.B12 | medicine |
design and development for potent and selective inhibitors of ADAMTS-4 and ADAMTS-5, which may be required for chronic osteoarthritis therapy |
709044 |
3.4.24.B12 | medicine |
ADAMTS5 is a biomarker for prediction of response to Infliximab in patients with rheumatoid arthritis |
709707 |
3.4.24.B12 | medicine |
overexpression of full-length ADAMTS5 suppresses B16 melanoma growth in mice. The reduced tumor growth is correlated with diminished tumor angiogenesis, together with reduced tumor cell proliferation and increased tumor cell apoptosis |
733058 |
3.4.24.B12 | medicine |
ADAMTS-5 is the main aggrecanase in laryngeal squamous cell carcinoma presenting a stage-related increase up to stage III (8fold higher expression compared to normal), and thereafter decreased in stage IV. ADAMTS-5 is highly expressed by carcinoma cells. Within the cancerous and their corresponding macroscopically normal laryngeal tissues, an altered distribution and organization of multiple molecular forms (latent, activated and fragmented forms) of the enzymes is found |
733436 |